Arcturus Therapeutics (ARCT) Tops Q1 EPS by $1.81
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
May 9, 2023 4:01 PM EDTNew Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval in 2023
$23.6 Million advanced for the manufacturing and supply of ARCT-154
ARCT-032 Phase 1 enrollment and administration completed successfully; trial expansion to include Cystic Fibrosis patients planned in third quarter
Investor conference call at 4:30 p.m. ET today
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company... More
